Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors
- Conditions
- MalignancyNeoplasmsAdvanced Solid TumorsCarcinomaCancer
- Interventions
- Biological: CVX-060
- Registration Number
- NCT00879684
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this study is to determine the safety and tolerability of CVX-060 in patients with advanced solid tumors.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 34
- Confirmed advanced solid tumors unresponsive to currently available therapies or for which there is no standard therapy.
- Adequate coagulation, liver, and renal function.
- Candidate for DCE-MRI evaluations.
- ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1.
- Evidence of significant bleeding problems.
- History of certain gastrointestinal problems including fistula and abscess.
- Chronic, uncontrolled hypertension.
- Patients with any history of primary or metastatic tumor involvement of the brain or with tumors that encase great vessels.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 CVX-060 -
- Primary Outcome Measures
Name Time Method Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) Baseline (Day 0) up to 30 days after last dose of study medication Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to CVX-060 was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.
- Secondary Outcome Measures
Name Time Method Maximum Observed Serum Concentration (Cmax) 0 hour (pre-dose) on Day 0 up to Day 7 of cycle 1 (28 days cycle) Serum Decay Half-Life (t1/2) 0 hour (pre-dose) on Day 0 up to Day 7 of cycle 1 (28 days cycle) Serum decay half-life is the time measured for the serum concentration to decrease by one half.
Time to Reach Maximum Observed Serum Concentration (Tmax) 0 hour (pre-dose) on Day 0 up to Day 7 of cycle 1 (28 days cycle) Area Under the Curve From Time Zero to 168 Hours [AUC (0-168)] 0 hour (pre-dose) on Day 0 up to Day 7 of cycle 1 (28 days cycle) AUC (0-168)= Area under the serum concentration versus time curve from time zero (pre-dose) to 168 hours after dosing (Day 7).
Apparent Volume of Distribution (Vss) 0 hour (pre-dose) on Day 0 up to Day 7 of cycle 1 (28 days cycle) Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after intravenous infusion dose (Vss) is influenced by the fraction absorbed.
Apparent Clearance (CL) 0 hour (pre-dose) on Day 0 up to Day 7 of cycle 1 (28 days cycle) Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes). Clearance obtained after intravenous infusion dose (apparent clearance) is influenced by the fraction of the dose absorbed.
Recommended Phase 2 Dose (RP2D): Stage 1 Baseline (Day 0) up to 42 days after the last dose of study medication RP2D was determined as the highest dose where none out of 3 (0/3) or less than or equal to 1 out of 6 (\<=1/6) participants experienced a dose limiting toxicity (DLT) or was determined based on the safety, pharmacokinetic, and pharmacodynamic findings. DLT was first course AE defined based on National Cancer Institute common toxicity criteria for adverse events version 3 (NCI-CTCAE Version 3) as any hematologic or non-hematologic toxicity greater than or equal to (\>=) Grade 3.
Number of Participants With Anti-CVX-060 Antibodies Baseline (Day 0) up to 42 days after last dose Number of Samples From Participants With Anti-CVX-060 Antibodies Baseline (Day 0) up to 42 days after last dose Number of Participants With Best Overall Response (BOR) Day 0 (predose), assessed every 8 weeks (2 cycles) until disease progression, unacceptable toxicity, or withdrawal for other reasons (up to Week 133) BOR: best response recorded from treatment start until disease progression/recurrence based on Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response (CR): disappearance of all lesions. Partial Response (PR): \>=30% decrease in sum of longest diameters (SLDs) of target lesions taking as reference baseline SLDs, associated to non-progressive disease (non-PD) response for non-target (NT) lesions. PD: \>=20% increase in SLDs of target lesions taking as reference smallest SLDs since treatment start, or appearance of \>=1 new lesion, or unequivocal progression in NT lesions. Stable disease (SD): neither shrinkage for CR/PR nor increase for PD taking as reference smallest SLDs since treatment start. CR and PR had to be confirmed on a follow up imaging assessment \>=4 weeks after initial objective documentation of response. SD criteria should be met at least once after start of treatment in a minimum interval of 8 weeks. Participants with \>=3 treatments cycles were reported.
Trial Locations
- Locations (4)
Premiere Oncology, A Medical Corporation
🇺🇸Santa Monica,, California, United States
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
Scottsdale Medical Imaging, Ltd.
🇺🇸Scottsdale, Arizona, United States
Premiere Oncology of Arizona
🇺🇸Scottsdale, Arizona, United States